

Severe Adverse Effects

- pericardial effusion / Delayed / 0-5.0
- myocardial infarction / Delayed / 0-5.0
- arrhythmia exacerbation / Early / 0-5.0
- atrial fibrillation / Early / 0-5.0
- cardiac arrest / Early / 0-5.0
- pericarditis / Delayed / 0-5.0
- bronchospasm / Rapid / 0-5.0
- pleural effusion / Delayed / 0-5.0
- agranulocytosis / Delayed / 0-5.0
- GI bleeding / Delayed / 0-5.0
- thrombosis / Delayed / 0-5.0

Moderate Adverse Effects

- antibody formation / Delayed / 1.0-61.0
- hyperlipidemia / Delayed / 7.0-7.0
- hypercholesterolemia / Delayed / 6.0-6.0
- peripheral edema / Delayed / 0-5.0
- encephalopathy / Delayed / 0-5.0
- chest pain (unspecified) / Early / 0-5.0
- hypertension / Early / 5.0-5.0
- sinus tachycardia / Rapid / 0-5.0
- palpitations / Early / 0-5.0
- impaired wound healing / Delayed / 0-5.0
- dyspnea / Early / 0-5.0
- subdural hematoma / Early / 0-5.0
- polycythemia / Delayed / 0-5.0
- cystitis / Delayed / 0-5.0 ^[1]

[1] - Humira (adalimumab) dose, indications, adverse effects, interactions... from PDR.net

<https://www.pdr.net/drug-summary/Humira-adalimumab-12.6151#12>, accessed: 2021-11-28

